XML 89 R31.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Segment Information | 12 Months Ended
--- | ---
Dec. 31, 2015
Segment Reporting [Abstract] |
Segment Information | Segment Information We operate as one operating segment, which is discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders, and, therefore, our chief operating decision-maker manages the operations of our company as a single operating segment. Enterprise-wide disclosures about product revenues, other revenues and long-lived assets by geographic area and information relating to major customers are presented below. Revenues are primarily attributed to individual countries based on location of the customer or licensee. Revenue by product is summarized as follows:
| For the Years Ended December 31,
| 2015 |  | 2014 |  | 2013
(In millions) | United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total
Multiple Sclerosis (MS): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
TECFIDERA | $ | 2,908.2 |  |  | $ | 730.2 |  |  | $ | 3,638.4 |  |  | $ | 2,426.6 |  |  | $ | 482.6 |  |  | $ | 2,909.2 |  |  | $ | 864.4 |  |  | $ | 11.7 |  |  | $ | 876.1 |
AVONEX | 1,790.2 |  |  | 840.0 |  |  | 2,630.2 |  |  | 1,956.7 |  |  | 1,056.4 |  |  | 3,013.1 |  |  | 1,902.4 |  |  | 1,103.1 |  |  | 3,005.5 |
PLEGRIDY | 227.1 |  |  | 111.4 |  |  | 338.5 |  |  | 27.8 |  |  | 16.7 |  |  | 44.5 |  |  | — |  |  | — |  |  | — |
TYSABRI | 1,103.1 |  |  | 783.0 |  |  | 1,886.1 |  |  | 1,025.1 |  |  | 934.4 |  |  | 1,959.5 |  |  | 814.2 |  |  | 712.3 |  |  | 1,526.5 |
FAMPYRA | — |  |  | 89.7 |  |  | 89.7 |  |  | — |  |  | 80.2 |  |  | 80.2 |  |  | — |  |  | 74.0 |  |  | 74.0 |
Hemophilia: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ELOCTATE | 308.3 |  |  | 11.4 |  |  | 319.7 |  |  | 58.4 |  |  | — |  |  | 58.4 |  |  | — |  |  | — |  |  | — |
ALPROLIX | 208.9 |  |  | 25.6 |  |  | 234.5 |  |  | 72.1 |  |  | 3.9 |  |  | 76.0 |  |  | — |  |  | — |  |  | — |
Other product revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
FUMADERM | — |  |  | 51.4 |  |  | 51.4 |  |  | — |  |  | 62.5 |  |  | 62.5 |  |  | — |  |  | 60.2 |  |  | 60.2 |
Total product revenues | $ | 6,545.8 |  |  | $ | 2,642.7 |  |  | $ | 9,188.5 |  |  | $ | 5,566.7 |  |  | $ | 2,636.7 |  |  | $ | 8,203.4 |  |  | $ | 3,581.0 |  |  | $ | 1,961.3 |  |  | $ | 5,542.3 |
Geographic Information The following tables contain certain financial information by geographic area:
December 31, 2015 (In millions) | U.S. |  | Europe(1) |  | Germany |  | Asia |  | Other |  | Total
Product revenues from external customers | $ | 6,545.8 |  |  | $ | 1,497.6 |  |  | $ | 668.1 |  |  | $ | 143.7 |  |  | $ | 333.3 |  |  | $ | 9,188.5 |
Unconsolidated joint business revenues | $ | 1,269.8 |  |  | $ | 3.5 |  |  | $ | — |  |  | $ | — |  |  | $ | 65.9 |  |  | $ | 1,339.2 |
Other revenues from external customers | $ | 142.0 |  |  | $ | 29.6 |  |  | $ | 1.6 |  |  | $ | 62.9 |  |  | $ | — |  |  | $ | 236.1 |
Long-lived assets | $ | 1,296.5 |  |  | $ | 879.4 |  |  | $ | 2.3 |  |  | $ | 7.7 |  |  | $ | 1.7 |  |  | $ | 2,187.6 |
December 31, 2014 (In millions) | U.S. |  | Europe(1) |  | Germany |  | Asia |  | Other |  | Total
Product revenues from external customers | $ | 5,566.7 |  |  | $ | 1,383.9 |  |  | $ | 811.8 |  |  | $ | 112.8 |  |  | $ | 328.2 |  |  | $ | 8,203.4 |
Unconsolidated joint business revenues | $ | 1,117.1 |  |  | $ | 7.7 |  |  | $ | — |  |  | $ | — |  |  | $ | 70.6 |  |  | $ | 1,195.4 |
Other revenues from external customers | $ | 212.6 |  |  | $ | 31.6 |  |  | $ | 1.8 |  |  | $ | 58.5 |  |  | $ | — |  |  | $ | 304.5 |
Long-lived assets | $ | 1,055.5 |  |  | $ | 701.9 |  |  | $ | 2.5 |  |  | $ | 2.6 |  |  | $ | 3.2 |  |  | $ | 1,765.7 |
December 31, 2013 (In millions) | U.S. |  | Europe(1) |  | Germany |  | Asia |  | Other |  | Total
Product revenues from external customers | $ | 3,581.0 |  |  | $ | 1,170.2 |  |  | $ | 417.7 |  |  | $ | 93.2 |  |  | $ | 280.2 |  |  | $ | 5,542.3 |
Unconsolidated joint business revenues | $ | 1,087.3 |  |  | $ | 1.6 |  |  | $ | — |  |  | $ | 3.2 |  |  | $ | 33.9 |  |  | $ | 1,126.0 |
Other revenues from external customers | $ | 193.5 |  |  | $ | 26.1 |  |  | $ | 1.2 |  |  | $ | 43.1 |  |  | $ | — |  |  | $ | 263.9 |
Long-lived assets | $ | 984.4 |  |  | $ | 758.3 |  |  | $ | 2.5 |  |  | $ | 2.1 |  |  | $ | 3.3 |  |  | $ | 1,750.7 |
(1) | Represents amounts related to Europe less those attributable to Germany.
Revenues from Unconsolidated Joint Business Approximately 12%, 12% and 16% of our total revenues in 2015, 2014 and 2013, respectively, are derived from our joint business arrangement with Genentech. For additional information related to our collaboration with Genentech, please read Note 19, Collaborative and Other Relationships to these consolidated financial statements. Significant Customers We recorded revenue from two wholesalers accounting for 34% and 26% of gross product revenues in 2015, 33% and 27% of gross product revenues in 2014, and 32% and 24% of gross product revenues in 2013, respectively. Other As of December 31, 2015, 2014 and 2013, approximately $684.9 million, $676.0 million and $731.1 million, respectively, of our long-lived assets were related to our manufacturing facilities in Denmark.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 33 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 35 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration